Link between obesity, insulin resistance paves way for safer diabetes drugs
July 22nd, 2010 - 3:09 pm ICT by ANILondon, July 22 (ANI): Researchers have found a new molecular link between obesity and the action of diabetes drugs such as Avandia and Actos, which could pave the way for improved medications that are more selective and safer.
Scientists from Dana-Farber Cancer Institute and The Scripps Research Institute, led by Dr. Bruce Spiegelman, conducted the above study.
“Our findings strongly suggest that good and bad effects of these drugs can be separated by designing second-generation drugs that focus on the newly uncovered mechanism,” Nature quoted Spiegelman as saying.
Avandia and Actos, known generically as rosiglitazone and pioglitazone, are widely used to counteract the obesity-related abnormalities in insulin response that lead to diabetes.
The drugs act on a master regulatory protein called PPAR-gamma, primarily in fat cells, which governs genes involved in the body’s response to insulin.
Obesity resulting from a high-fat diet alters the function of PPAR-gamma and disrupts the expression of those insulin response genes, including adipsin and adiponectin.
Avandia and Actos work by binding to PPAR-gamma and reversing the gene expression changes.
The drugs were believed to work by stimulating or “agonizing” the PPAR-gamma receptor, causing it to rev up some genes and dampen the activity of others.
However, in the new study, researchers say that they have identified “an entirely new and surprising mechanism by which PPAR-gamma can control whole-body insulin sensitivity.”
They found that it is mainly through this mechanism that the diabetes drugs counteract insulin resistance - not their agonist effect on PPAR-gamma.
Moreover, they say, agonism of PPAR-gamma may be largely responsible for the harmful drug side effects.
The newly identified pathway linking obesity and insulin response involves cdk5, a protein kinase, or molecular “switch.”
When cdk5 is activated by the development of obesity in mice, it causes a chemical change in PPAR-gamma called phosphorylation.
In contrast to agonism of PPAR-gamma, phosphorylation has a narrow effect, disrupting a smaller set of genes that lead to insulin resistance.
In addition to agonizing PPAR-gamma, Avandia and Actos also block the phosphorylation of PPAR-gamma by cdk5.
It’s this latter effect that accounts for most of the drugs’ anti-diabetic benefits, the authors contend.
The study has been published in the latest issue of Nature. (ANI)
- Why a class of diabetes drugs boosts weight gain - May 02, 2011
- Could red wine treat diabetes? - Nov 20, 2010
- Our body clocks determine how much fat we burn - Nov 16, 2010
- Here's what causes the birth of a fat cell - Aug 17, 2010
- Diabetes medication safe for Alzheimer's patients - Sep 14, 2010
- Molecular 'switch' that contributes to cellular aging process identified - Dec 01, 2010
- Diabetes drug may boost power of anti-depressants - May 03, 2012
- 'Dual switch' that regulates fat formation may harbour obesity cure - Apr 09, 2011
- Micro-RNA that regulates insulin in obesity identified - Apr 01, 2011
- Diabetes or lipid-lowering medications may help treat addiction - Apr 06, 2011
- Genetic discovery could pave way for obesity, diabetes treatments - Aug 27, 2009
- New drug murders cancer cells - Apr 08, 2010
- Diabetes drug can raise heart disease risk by 25 percent - Mar 18, 2011
- Grape compound increases beneficial fat hormone - Jan 08, 2011
- The Diabetes Drugs, Avandia and Actos, Have The Same Amount of Risks - Aug 29, 2010
Tags: adiponectin, avandia, dana farber cancer, dana farber cancer institute, diabetes drugs, farber cancer institute, fat cells, gene expression changes, insulin resistance, insulin response, insulin sensitivity, molecular switch, pioglitazone, ppar gamma, protein kinase, regulatory protein, response genes, rosiglitazone, scripps research institute, spiegelman